Claims
- 1. Method for the treatment of humans for combating and preventing disorders which are caused by a restriction in cerebral function, and for the treatment of cerebral aging processes, which comprises administering to a human subject to or afflicted with such disorders and for aging processes an effective dose of 2-(aminoalkyl)-pyrrole derivative of the formula I ##STR8## wherein R denotes hydrogen, alkyl(C.sub.1 -C.sub.5) or phenyl;
- R.sup.1 denotes hydrogen, alkyl(C.sub.1 -C.sub.5), cyano-alkyl(C.sub.1 -C.sub.4), alkoxy(C.sub.1 -C.sub.4)-carbonyl, alkoxy(C.sub.1 -C.sub.4)-carbonyl-alkyl(C.sub.1 -C.sub.4); R.sup.7 (R.sup.8)N-carbonylalkyl(C.sub.1 -C.sub.4), acetyl-amino-ethyl, phenyl or phenyl-alkyl(C.sub.1 -C.sub.4), it being possible for the phenyl or the phenyl of the phenyl-alkyl also to be monosubstituted or polysubstituted by halogen, alkoxy(C.sub.1 -C.sub.4), alkyl(C.sub.1 -C.sub.4), R.sup.4 (R.sup.5)N-, hydroxyl, mercapto, alkylmercapto(C.sub.1 -C.sub.4), nitro, cyano, alkoxy(C.sub.1 -C.sub.4)-carbonyl or alkoxy(C.sub.1 -C.sub.4)-carbonyl-alkyl(C.sub.1 -C.sub.4) or R.sup.1 denotes R.sup.4 (R.sup.5)N-R.sup.6 -, hydroxy-carbonyl-alkyl(C.sub.1 -C.sub.4), 1-(alkoxy(C.sub.1 -C.sub.4)-carbonyl)-2-mercapto-ethyl, 1-(alkoxy(C.sub.1 -C.sub.4)-carbonyl)-2-hydroxy-ethyl, 1-(alkoxy(C.sub.1 -C.sub.4)-carbonyl)-2-alkoxy(C.sub.1 -C.sub.4)-ethyl, 1-(alkoxy(C.sub.1 -C.sub.4)-carbonyl-2-alkylthio(C.sub.1 -C.sub.4)-ethyl, 1-(alkoxy(C.sub.1 -C.sub.4)-carbonyl)-2-(alkyl(C.sub.1 -C.sub.4)-carbonyl-thio)-ethyl, 1-(alkoxy(C.sub.1 -C.sub.4)-carbonyl)-2-(alkyl(C.sub.1 -C.sub.4)-carbonyl-oxy)-ethyl, or 1-(alkoxy(C.sub.1 -C.sub.4)-carbonyl)-2-phenyl-ethyl;
- R.sup.2 und R.sup.3 independently of one another denote hydrogen, alkyl(C.sub.1 -C.sub.5), alkanoyl(C.sub.1 -C.sub.5), alkanoyl(C.sub.2 -C.sub.5) which is mono-, di- or tri-substituted by amino, alkoxy(C.sub.1 -C.sub.4), hydroxyl, alkanoyloxy(C.sub.1 -C.sub.4), phenyl or halogen, phenylcarbonyl, phenylcarbonyl which is mono- or polysubstituted by halogen, alkoxy(C.sub.1 -C.sub.4), alkyl(C.sub.1 -C.sub.4), amino, R.sup.4 (R.sup.5)N-, hydroxy, alkanoyloxy(C.sub.1 -C.sub.4), mercapto, alkylmercapto(C.sub.1 -C.sub.4), nitro, cyano, alkoxy(C.sub.1 -C.sub.4)-carbonyl or aminosulphonyl, or R.sup.2 and/or R.sup.3 denote cycloalkylcarbonyl with 5 to 7 C atoms in the cycloalkyl radical or (4-chlorophenoxy)-acetyl;
- R.sup.4 and R.sup.5 denote hydrogen or alkyl(C.sub.1 -C.sub.4);
- R.sup.6 denotes alkylene(C.sub.1 -C.sub.4);
- R.sup.7 and R.sup.8 independently of one another denote hydrogen or alkyl(C.sub.1 -C.sub.4);
- and n denotes 1, 2 or 3, or a pharmacologically acceptable acid addition salt thereof.
- 2. Method according to claim 1, wherein a derivative of formula I is administered in which R denotes methyl.
- 3. Method according to claim 1, wherein a derivative of formula I is administered in which R.sup.3 denotes hydrogen, 3,4-dimethoxybenzoyl, 4-chlorobenzoyl, 4-chlorophenoxyacetyl or acetyl.
- 4. Method according to claim 1, wherein a derivative of formula I is administered in which R.sup.1 denotes hydrogen, 2-dimethylaminoethyl, 3,4-dimethoxyphenyl-ethyl, 4,5-dimethoxy-2-(methoxycarbonyl)-phenyl, methoxycarbonylmethyl, acetylamino-ethyl, cyanoethyl, 2-methoxy-carbonyl-phenyl, 2-methoxy-carbonyl-, 4,5,6-trimethoxy-phenyl or aminocarbonylmethyl.
- 5. Method according to claim 1, wherein 5-Methyl-2-(3,4-dimethoxybenzoyl-amino-methyl)-pyrrole is administered.
- 6. Method according to claim 1, wherein 1-(2-Methoxycarbonyl-4,5-dimethoxy-phenyl)-5-methyl-2-(4-chlorophenoxy-acetylamino-methyl)-pyrrole is administered.
- 7. Pharmaceutical product useful for the treatment of humans for combating and preventing disorders which are caused by a restriction in cerebral function, and for the treatment of cerebral aging processes, said product comprising an effective amount of a pharmacologically-active compound and a physiologically-acceptable, pharmacologically-inert excipient, said active compound comprising a 2-(aminoalkyl)-pyrrole derivative of the formula I ##STR9## wherein R denotes hydrogen, alkyl(C.sub.1 -C.sub.5) or phenyl;
- R.sup.1 denotes hydrogen, alkyl(C.sub.1 -C.sub.5), cyano-alkyl(C.sub.1 -C.sub.4), alkoxy(C.sub.1 -C.sub.4)-carbonyl, alkoxy(C.sub.1 -C.sub.4)-carbonyl-alkyl(C.sub.1 -C.sub.4); R.sup.7 (R.sup.8)N-carbonylalkyl(C.sub.1 -C.sub.4), acetyl-amino-ethyl, phenyl or phenyl-alkyl(C.sub.1 -C.sub.4), it being possible for the phenyl or the phenyl of the phenyl-alkyl also to be monosubstituted or polysubstituted by halogen, alkoxy(C.sub.1 -C.sub.4), alkyl(C.sub.1 -C.sub.4), R.sup.4 (R.sup.5)N-, hydroxyl, mercapto, alkylmercapto(C.sub.1 -C.sub.4), nitro, cyano, alkoxy(C.sub.1 -C.sub.4)-carbonyl or alkoxy(C.sub.1 -C.sub.4)-carbonyl-alkyl(C.sub.1 -C.sub.4) or R.sup.1 denotes R.sup.4 (R.sup.5)N-R.sup.6 -, hydroxy-carbonyl-alkyl(C.sub.1 -C.sub.4), 1-(alkoxy(C.sub.1 -C.sub.4)-carbonyl)-2-mercapto-ethyl, 1-(alkoxy(C.sub.1 -C.sub.4)-carbonyl)-2-hydroxy-ethyl, 1-(alkoxy(C.sub.1 -C.sub.4)-carbonyl)-2-alkoxy(C.sub.1 -C.sub.4)-ethyl, 1(alkoxy(C.sub.1 -C.sub.4)-carbony-2-alkylthio(C.sub.1 -C.sub.4)-ethyl, 1-(alkoxy(C.sub.1 -C.sub.4)-carbonyl)-2-(alkyl(C.sub.1 -C.sub.4 )-carbonyl-thio)-ethyl, 1(alkoxy(C.sub.1 -C.sub.4)-carbonyl)-2-(alkyl(C.sub.1 -C.sub.4)-carbonyl-oxy)-ethyl, or 1-(alkoxy(C.sub.1 -C.sub.4)-carbonyl)-2-phenyl-ethyl;
- R.sup.2 und R.sup.3 independently of one another denote hydrogen, alkyl(C.sub.1 -C.sub.5), alkanoyl(C.sub.1 -C.sub.5), alkanoyl(C.sub.2 -C.sub.5) which is mono-, di- or tri-substituted by amino, alkoxy(C.sub.1 -C.sub.4), hydroxyl, alkanoyloxy(C.sub.1 -C.sub.4), phenyl or halogen, phenylcarbonyl, phenylcarbonyl which is mono- or polysubstituted by halogen, alkoxy(C.sub.1 -C.sub.4), alkyl(C.sub.1 -C.sub.4), amino, R.sup.4 (R.sup.5)N-, hydroxy, alkanoyloxy(C.sub.1 -C.sub.4), mercapto, alkylmercapto(C.sub.1 -C.sub.4), nitro, cyano, alkoxy(C.sub.1 -C.sub.4)-carbonyl or aminosulphonyl, or R.sup.2 and/or R.sup.3 denote cycloalkylcarbonyl with 5 to 7 C atoms in the cycloalkyl radical or (4-chlorophenoxy)-acetyl;
- R.sup.4 and R.sup.5 denote hydrogen or alkyl(C.sub.1 -C.sub.4);
- R.sup.6 denotes alkylene(C.sub.1 -C.sub.4);
- R.sup.7 and R.sup.8 independently of one another denote hydrogen or alkyl(C.sub.1 -C.sub.4);
- and n denotes 1, 2 or 3, or a pharmaceutically acceptable acid addition salt thereof.
- 8. Pharmaceutical product according to claim 7, wherein R of the active compound is methyl.
- 9. Pharmaceutical product according to claim 7, wherein R.sup.3 of the active compound denotes hydrogen, 3,4-dimethoxybenzoy, 4-chlorobenzoy, 4-chlorophenoxyacetyl or acetyl.
- 10. Pharmaceutical product according to claim 7, wherein R.sup.1 of the active compound denotes hydrogen, 2-dimethylaminoethyl, 3,4-dimethoxyphenyl-ethyl, 4,5-dimethoxy-2-(methoxycarbonyl)-phenyl, methoxycarbonylmethyl, acetylamino-ethyl, cyanoethyl, 2-methoxy-carbonyl-phenyl, 2-methoxy-carbonyl-, 4,5,6-trimethoxy-phenyl or aminocarbonylmethyl.
- 11. Pharmaceutical product according to claim 7, wherein the active compound is 5-Methyl-2-(3,4-dimethoxybenzoylamino-methyl)-pyrrole.
- 12. Pharmaceutical product according to claim 7, wherein the active compound is 1-(2-Methoxy-carbonyl-4,5-dimethoxy-phenyl)-5-methyl-2-(4-chlorophenoxy-acetylaminomethyl)-pyrrole.
Parent Case Info
This is a divisional of co-pending application Ser. No. 604,533 filed on Apr. 27, 1984, now abandoned.
Divisions (1)
|
Number |
Date |
Country |
Parent |
604533 |
Apr 1984 |
|